Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Novel IDO Inhibitor Yields Durable Responses in Metastatic Pancreatic Cancer
April 21st 2016Novel therapy with indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, in combination with standard chemotherapy, yielded a response rate of 42% as first-line therapy for metastatic pancreatic adenocarcinoma
Read More
Telotristat Etiprate Application for Carcinoid Syndrome Submitted to FDA
March 31st 2016A new drug application (NDA) has been submitted to the FDA for telotristat etiprate as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs), according to a statement from the drug's developer, Lexicon Pharmaceuticals.
Read More
FDA Approves Defibrotide in Hepatic VOD Post-Stem Cell Transplantation
March 31st 2016The FDA has approved defibrotide sodium (Defitelio) as a treatment for severe hepatic veno-occlusive disease (VOD) with associated kidney or lung abnormalities following hematopoietic stem cell transplantation (HSCT), based on data from the collection of 3 studies.
Read More
Benefits Observed with Second-Line Therapy in Metastatic Pancreatic Cancer
March 30th 2016Second-line treatment of metastatic pancreatic cancer, after first-line treatment with nab-paclitaxel plus gemcitabine or gemcitabine alone, is feasible and may improve outcomes, according to a post-hoc analysis of the phase 3 MPACT trial presented at the 2016 Gastrointestinal Cancers Symposium.
Read More
Exploration Into Stereotactic Body Radiation Therapy for Pancreatic Cancer
March 29th 2016New technology and improvements in administration techniques could make the utilization of stereotactic body radiation therapy easier and more plausible for patients with pancreatic cancer, according to Joseph Michael Herman, MD.
Read More
Liposomal Irinotecan Combo Added to NCCN Guideline for Pancreatic Cancer in Second-Line
March 26th 2016Liposomal irinotecan (irinotecan liposome injection; Onivyde), fluorouracil (5-FU), and leucovorin in combination has been added to the 2016 NCCN Clinical Practice Guidelines in Oncology as a second-line treatment for patients with gemcitabine-refractory metastatic pancreatic cancer.
Read More
New PER Event Focuses on GI Cancers
March 25th 2016On Saturday, April 23, 2016, Physicians' Education Resource, LLC (PER) will help to fill the education gap inherent in some of the most difficult-to-treat forms of gastrointestinal (GI) cancer, with the first annual School of Gastrointestinal Oncology (SOGO), which will be held at the Grand Hyatt in New York City.
Read More
Nab-Paclitaxel Plus Gemcitabine Opens Up Treatment Options in Pancreatic Cancer
March 16th 2016The combination of nab-paclitaxel (Abraxane) and gemcitabine is steadily gaining in popularity among oncologists in the treatment armamentarium for pancreatic adenocarcinoma, according to Fadi Braiteh, MD.
Read More
Earlier Nab-Paclitaxel/Gemcitabine Explored in Pancreatic Cancer
March 15th 2016A bevy of clinical trials exploring the use of nab-paclitaxel (Abraxane) in various combinations and treatment settings aim to uncover future strategies for treating patients with pancreatic adenocarcinoma, which remains one of the deadliest forms of cancer.
Read More
Ziv-Aflibercept Plus Capecitabine Combo Active, Well-Tolerated in mCRC
March 2nd 2016The combination of ziv-aflibercept and capecitabine demonstrated an acceptable safety profile and encouraging clinical efficacy for patients with metastatic colorectal cancer, according to findings from the ongoing phase II X-TRAP trial.
Read More
Everolimus Receives FDA Approval for GI, Lung NETs
February 27th 2016Everolimus (Afinitor) has received FDA approval for adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal (GI) or lung neuroendocrine tumors (NET), based on findings from the phase III RADIANT-4 trial.
Read More
ERCC1 Expression Falls Short as Chemo Biomarker in mCRC
February 18th 2016A potential biomarker to guide the treatment of patients with metastatic colorectal cancer (mCRC) failed to stratify patients by progression-free survival (PFS) or responsiveness to bevacizumab, according to a randomized trial.
Read More
Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs
February 17th 2016The trial looked at radionuclide therapy Lu-Dotatate in patients with advanced midgut neuroendocrine tumors (NETs), and showed an improvement in overall survival and the reduction of progression or death risk by 79%.
Watch
FOLFOXIRI Bests FOLFOX as Bevacizumab Backbone in mCRC
February 17th 2016Marginal improvements were seen in clinical outcomes for patients with metastatic colorectal cancer (CRC) treated with FOLFOXIRI plus bevacizumab compared with FOLFOX plus bevacizumab; however, these findings were inconsistent, according to results from the phase II STEAM trial.
Read More
Case Study Suggests Regorafenib Remains Effective Beyond Progression for mCRC
February 9th 2016Many patients with metastatic colorectal cancer (CRC) will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.
Read More
Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors
February 6th 2016Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors.
Watch
Dr. Amitabh Chak on New Screening Methods for Esophageal Cancer
February 5th 2016Amitabh Chak, MD, MS, professor of Medicine, director, Clinical Research, Division of Gastroenterolgy Diseases, Case Western Reserve University, discusses advances in esophageal cancer. Chak says some of the more "exciting" developments in the treatment of the disease are transnasal endoscopy, as well as a new type of screening device that acts as a "pap smear" for the esophagus.
Watch